SCHEMBL8221027

SCHEMBL8221027

CCC(C)Cc1ccccc1OC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.48
TAAR1 Q96RJ0 1/20 0.48
ALDH1A1 P00352 2/20 0.47
CHRM2 P08172 1/20 0.47
CHRM1 P11229 1/20 0.47
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
ATM Q13315 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA4 P22748 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
TSHR P16473 1/20 0.44
HPGD P15428 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23961372 1.00 IDO1 (0.48) IDO1TAAR1ALDH1A1CHRM2CHRM1
SCHEMBL4450092 0.83 IDO1 (0.47) IDO1TAAR1ALDH1A1CHRM2CHRM1
SCHEMBL27757418 0.83 ALDH1A1 (0.50) IDO1TAAR1ALDH1A1CHRM2CHRM1
SCHEMBL6014412 0.83 TAAR1 (0.56) IDO1TAAR1ALDH1A1CHRM2CHRM1
SCHEMBL18505011 0.83 LMNA (0.50) IDO1TAAR1ALDH1A1CHRM2CHRM1
SCHEMBL765677 0.83 LMNA (0.50) IDO1TAAR1ALDH1A1CHRM2CHRM1
SCHEMBL748982 0.83 LMNA (0.50) IDO1TAAR1ALDH1A1CHRM2CHRM1
SCHEMBL878976 0.82 IDO1 (0.53) IDO1TAAR1ALDH1A1CHRM2CHRM1
SCHEMBL9239502 0.81 ALDH1A1 (0.49) IDO1TAAR1ALDH1A1CHRM2CHRM1
SCHEMBL7630641 0.81 GABRA1 (0.39) TAAR1TSHRHTTSIGMAR1SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210332064-A1 ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER GENENTECH, INC. (US) 2021-10-28 US disclosed
WO-2008033460-A2 TREATING PAIN, DIABETES, AND LIPID METABOLISM DISORDERS SCHERING CORPORATION (US) 2008-03-20 WO disclosed
WO-2008033456-A1 SPIRO-CONDENSED AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABILISM SCHERING CORPORATION (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210332064-A1 ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CANCER PGK1, PHKG1, NEK1 IDO1 776/4885TAAR1 4542/4885ALDH1A1 3038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.